Literature DB >> 20484868

Effect of an herbal preparation, STW 5, in an acute model of reflux oesophagitis in rats.

Heba Abdel-Aziz1, Hala F Zaki, Winfried Neuhuber, Olaf Kelber, Dieter Weiser, Mohamed T Khayyal.   

Abstract

A multitarget herbal preparation, STW 5, has been used clinically in different gastro-intestinal disorders including functional dyspepsia and irritable bowel syndrome. Previous studies have shown that it possesses properties that may render it useful in gastro-oesophageal reflux disease (GERD). We performed this study to test this compound in an acute model of reflux oesophagitis in rats. Oesophagitis was induced surgically by ligating the pyloric end and fore-stomach. Lower oesophageal pH was measured 3 h later in conscious animals. Five hours after surgery, animals were sacrificed and the oesophagi were examined macroscopically and histologically. Selected markers of inflammation were measured in oesophageal homogenates. STW 5 was given orally for 5 days before induction of oesophagitis. Pantoprazole was used as a reference standard. Ligated animals showed a high incidence of ulcerative lesions associated with a marked increase in myeloperoxidase, thiobarbituric acid-reactive substances, tumor necrosis factor-alpha, and interleukin-1beta. STW 5 did not affect oesophageal pH, but dose-dependently reduced the severity of the oesophageal lesions and normalized the deranged level of the inflammation markers. The beneficial effects were confirmed histopathologically. STW 5 proved to be effective in protecting against inflammatory lesions in this model of oesophagitis, thus warranting further investigation of its potential therapeutic usefulness in GERD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484868     DOI: 10.1254/jphs.09355fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

1.  GPR84 and TREM-1 Signaling Contribute to the Pathogenesis of Reflux Esophagitis.

Authors:  Heba Abdel-Aziz; Mathias Schneider; Winfried Neuhuber; Abdel Meguid Kassem; Saleem Khailah; Jürgen Müller; Hadeel Gamal Eldeen; Ahmed Khairy; Mohamed T Khayyal; Anastasiia Shcherbakova; Thomas Efferth; Gudrun Ulrich-Merzenich
Journal:  Mol Med       Date:  2016-05-09       Impact factor: 6.354

2.  Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells.

Authors:  Mathias Schneider; Thomas Efferth; Heba Abdel-Aziz
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

Review 3.  Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.

Authors:  Ahmed Madisch; Bettina R Vinson; Heba Abdel-Aziz; Olaf Kelber; Karen Nieber; Karin Kraft; Martin Storr
Journal:  Wien Med Wochenschr       Date:  2017-04-19

4.  Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin.

Authors:  Yingqin Deng; Li Pan; Wenjie Qian
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

5.  STW 5 is effective in dextran sulfate sodium-induced colitis in rats.

Authors:  Walaa Wadie; Heba Abdel-Aziz; Hala F Zaki; Olaf Kelber; Dieter Weiser; Mohamed T Khayyal
Journal:  Int J Colorectal Dis       Date:  2012-05-06       Impact factor: 2.571

Review 6.  Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast.

Authors:  Heba Abdel-Aziz; Olaf Kelber; Gerhard Lorkowski; Martin Storr
Journal:  Planta Med       Date:  2017-08-31       Impact factor: 3.352

7.  STW 5 is effective against nonsteroidal anti-inflammatory drugs induced gastro-duodenal lesions in rats.

Authors:  Mohamed T Khayyal; Walaa Wadie; Enas A Abd El-Haleim; Kawkab A Ahmed; Olaf Kelber; Ramy M Ammar; Heba Abdel-Aziz
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.